Concomitant use of sodium-glucose co-transporter 2 inhibitors and metformin and the risk of osteomyelitis reporting: a disproportionality analysis based on FAERS database
This study showed an increased risk of SGLT2i-associated osteomyelitis, focusing on canagliflozin, and presented a potential association between amputation and osteomyelitis, providing a reference for the clinical practice of diabetes with SGLT2i medication.
Authors
- Xin Wang (ORCID: https://orcid.org/0000-0002-7592-7789)
- Shenyin Zhu (ORCID: https://orcid.org/0000-0001-5739-5603)
- Jiangfan Wu (ORCID: https://orcid.org/0000-0002-0565-7760)
- Xiaofang Zhao
Institutions
- Kaili University (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-22
- DOI
- https://doi.org/10.1080/14740338.2024.2446431
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00